The incidence of colorectal cancer continues to increase in both sexes, and, worryingly, among the population under 50 years of age. One in five patients diagnosed with disseminated disease (with distant metastasis) or in them the disease will relapse even if they have been operated.
A new treatment scheme would reinforce the approach to these patients. The combination of trifluridine/tipiracil plus bevacizumab improves survival in patients with metastatic colon cancer treated with two standard chemotherapy regimens.